Europe — EMA
Opfolda (Miglustat)
Miglustat, the active ingredient in Opfolda, is a substrate reduction therapy presented as a oral tablet for oral use. It is used in the treatment of rare metabolic disorders such as Niemann-Pick disease type C and…
Request sourcing
1
Pack/s
What is Miglustat?
Miglustat, the active ingredient in Opfolda, is a substrate reduction therapy presented as a oral tablet for oral use. It is used in the treatment of rare metabolic disorders such as Niemann-Pick disease type C and Gaucher disease type 1 in adults and children.
GNH USA supplies Opfolda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Miglustat used for?
Opfolda (miguel ???) is ....
- Niemann‑PICK S .... .... .... ... .... .... ........ .... ...
What are the side effects of Miglustat?
Common
Product details
Drug
Miglustat
Route
Oral Use
Manufacturer
Amicus Therapeutics Europe Limited
Origin
EU
